Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

Journal Browser

Endometrial Cancer: State-of-the-Art and Clinical Perspective

Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: closed (25 September 2024) | Viewed by 7939

Share This Special Issue

Special Issue Editor

Dr. Francesco Plotti

E-Mail Website
Guest Editor

Department of Obstetrics and Gynecology, University Campus Biomedico of Rome, Rome, Italy
Interests: surgical oncology; screening; laparoscopic surgery laparoscopic; urinary incontinence; oncology; laparoscopy; gynecologic oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endometrial carcinoma is the most common gynecologic malignancy, and the incidence of endometrial carcinoma is estimated to increase by 1–2% every year.Treatment modalities in endometrial cancer vary depending on the grade and the stage of the disease. In recent years, sentinel lymph node (SLN) sampling has been advocated as an alternative to standard hysterectomy with complete lymphadenectomy. Surgery is the standard treatment for early-stage endometrial cancer. Additional treatment, depending on the stage of the disease, may include radiation with or without chemotherapy, hormone therapy, immunotherapy, and some targeted therapies. Several new treatments for advanced disease have become available. Determining the molecular subtypes of cancers and deciding treatment according to type have both impacted practice. Other advances in this field include the use of immunotherapy and targeted therapies. This Special Issue aims to report the last advancements regarding the current understanding of endometrial cancer, including genetic background, molecular targeting, surgical management, and adjuvant treatment.

Dr. Francesco Plotti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

endometrial cancer
sentinel node
immounotherapy
target therapies
hormone therapy

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Other

12 pages, 6329 KiB

Open AccessArticle

Pilot Data Suggest That Obesity and Presence of Malignancy Are Associated with Altered Immune Cell Infiltration in Endometrial Biopsies

by Eline Jacques, Anouk van den Bosch, Peggy de Vos van Steenwijk, Loes Kooreman, Bert Delvoux, Andrea Romano and Henrica Werner

J. Clin. Med. 2024, 13(23), 7248; https://doi.org/10.3390/jcm13237248 - 28 Nov 2024

Viewed by 1065

Abstract

(1) Background: The worldwide endometrial cancer (EC) incidence is rising, amongst others linked to obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, possibly due to low-grade adipose tissue inflammation. We studied immune cell infiltration in the endometrium in relation to diagnosis and obesity. (2) Methods: A cohort was created (n = 44) from postmenopausal women, lean (n = 15) and obese (n = 29), with bleeding complaints due to EC (n = 18) or benign pathology (n = 26). Endometrial biopsies were used to study the immune microenvironment and stained for macrophages (CD68 and CD163), T-cells (CD3 and CD8), and NK-cells (CD56). (3) Results: Malignant samples showed reduced intraepithelial CD3+ and CD8+ T-cells and increased stromal CD3+ T-cells. In obese patients, increased intraepithelial CD3+ and CD8+ T-cells were detected, especially in obese patients with T2DM. Epithelial CD56+ NK-cells were depleted in EC; however, no effect of obesity on NK-cell infiltration was observed. Stromal CD68+ cells were reduced in EC patients, whereas the CD163+ cells were increased. (4) Conclusions: Obesity and malignancy are associated with differences in immune cell presence. The alterations in immune cell infiltration seen in obese EC patients with and without diabetes suggest a complex interaction where obesity-related low-grade inflammation plays a central role. Full article

(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)

► Show Figures

Figure 1

13 pages, 1354 KiB

Open AccessArticle

Predictive Role of Pre-Operative Anemia in Early Recurrence of Endometrial Cancer: A Single-Center Study in Romania

by Mihaela Ionică, Marius Biris, Florin Gorun, Nicoleta Nicolae, Zoran Laurentiu Popa, Maria Cezara Muresan, Marius Forga, Dragos Erdelean, Izabella Erdelean, Mihai Adrian Gorun and Octavian Constantin Neagoe

J. Clin. Med. 2024, 13(3), 794; https://doi.org/10.3390/jcm13030794 - 30 Jan 2024

Viewed by 1720

Abstract

This study aims to investigate the association between anemia and early recurrence in endometrial cancer patients. We retrospectively analyzed the data of 473 endometrial cancer patients treated at our hospital from January 2015 to December 2020. Patients were divided into two groups based on their hemoglobin (Hb) level: anemia group (Hb < 12 g/dL) and non-anemia group (Hb ≥12 g/dL). Early recurrence was defined as recurrence within 2 years of diagnosis. Univariate and multivariate logistic regression analyses were used to identify the predictors of early recurrence. The prevalence of anemia was 38.26% (181/473). The incidence of early recurrence was 12.89% (61/473) in the anemia group and 9.24% (38/412) in the non-anemia group (p = 0.004). Univariate analysis showed that anemia was a significant predictor of early recurrence (odds ratio (OR) = 2.27, 95% confidence interval (CI): 1.35–3.80, p = 0.003). Multivariate analysis confirmed that anemia was an independent predictor of early recurrence (OR = 2.11, 95% CI: 1.21–3.84, p = 0.01). Anemia is an independent predictor of early recurrence in endometrial cancer patients. Patients with endometrial cancer should be screened for anemia and treated if present. Additionally, patients with anemia should be closely monitored for early signs of recurrence and treated aggressively. Full article

(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)

► Show Figures

Figure 1

11 pages, 594 KiB

Open AccessArticle

Impact of COVID-19 Pandemic on the Diagnostic and Therapeutic Management of Endometrial Cancer: A Monocentric Retrospective Comparative Study

by Francesco Plotti, Adele Silvagni, Roberto Montera, Carlo De Cicco Nardone, Daniela Luvero, Fernando Ficarola, Gianna Barbara Cundari, Francesco Branda, Roberto Angioli and Corrado Terranova

J. Clin. Med. 2023, 12(22), 7016; https://doi.org/10.3390/jcm12227016 - 9 Nov 2023

Viewed by 1561

Abstract

Endometrial cancer represents an ideal target to evaluate the impact of COVID-19 being the most frequent gynecological malignancy in Italy, generally detected at early stages and correlated with favorable oncological outcomes. The present comparative retrospective study carried out at Campus Bio-medico University Foundation in Rome aims to evaluate the impact of the COVID-19 pandemic on the presentation, diagnosis and treatment of EC. All women with a histological diagnosis of non-endometrioid and endometrioid endometrial cancer between 1 March 2018 and 31 October 2022 were included. The number of cases was higher in period 2 (95 vs. 64 cases). Time to diagnosis did not show statistically significant differences but in period 2, 92.06% of the diagnoses were made following abnormal uterine bleeding, while in period 1, only 67.02% were. The waiting time for the intervention was significantly shorter in period 2. Definitive histology, FIGO staging, surgical technique and adjuvant therapy did not show significant differences between the two periods. The study demonstrates that the impact of the COVID-19 pandemic did not have a direct effect on the diagnostic delay, tumor staging and type of therapy but rather on the presentation pattern of endometrial cancer. Full article

(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)

► Show Figures

Figure 1

Other

Jump to: Research

14 pages, 1551 KiB

Open AccessSystematic Review

PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature

by Orazio De Tommasi, Matteo Marchetti, Marta Tripepi, Sofia Bigardi, Giosuè Giordano Incognito, Valentina Tuninetti, Emma Facchetti, Giulia Tasca, Marco Noventa, Carlo Saccardi, Roberto Tozzi and Giulia Spagnol

J. Clin. Med. 2025, 14(2), 401; https://doi.org/10.3390/jcm14020401 - 10 Jan 2025

Cited by 1 | Viewed by 1763

Abstract

Background/Objectives: Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), present in approximately 30% of cases. This review evaluated PD-L1 and PD-1 expression as potential biomarkers for immunotherapy response in EC, focusing on their relationship with MSI status. Methods: A systematic review, adhering to PRISMA guidelines, analyzed studies from MEDLINE and Embase until February 2023 on PD-1/PD-L1 expression in EC stratified by MSI status, including diverse study designs but excluding conference abstracts, with independent screening, data extraction, and additional reference checks to ensure comprehensive coverage. Results: A systematic analysis of 10 studies found that PD-L1 expression was more frequently expressed in MSI tumors (49%) compared to microsatellite-stable tumors (MSS) (33.5%), while PD-1 was expressed in 58% of MSI cases and 48% of MSS cases. Despite these findings, the prognostic value of PD-L1/PD-1 remains uncertain, with conflicting results regarding their association with survival outcomes. PD-L1 expression varied across molecular subtypes, being highest in POLE-mutated tumors (76.56%) and serous carcinomas (73%). Differences in PD-L1 expression between primary and metastatic sites were also noted, complicating its use as a biomarker. Conclusions: The assessment of PD-L1 expression in EC could represent a valuable option for selecting patients who may benefit from immune checkpoint inhibitors (ICI), including those in the MSS cohort, thereby ensuring a more tailored and personalized treatment strategy. Full article

(This article belongs to the Special Issue Endometrial Cancer: State-of-the-Art and Clinical Perspective)

► Show Figures

Journal Menu

Journal Browser

Endometrial Cancer: State-of-the-Art and Clinical Perspective

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (4 papers)

Research

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI